Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.5 CHF | +1.15% |
|
-3.19% | +11.90% |
06-20 | Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit | MT |
06-20 | Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.90% | 525M | |
+16.43% | 45.51B | |
-9.66% | 38.52B | |
+38.08% | 38.13B | |
+28.02% | 30.74B | |
-8.64% | 26.03B | |
+11.93% | 25.92B | |
+45.08% | 14.13B | |
+33.68% | 12.73B | |
-7.84% | 11.29B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cancer Patients